Questionnaire PLD‐complaint‐specific assessment identifies need for therapy in polycystic liver disease: A multi‐centric prospective study
Authors:
Open Access
- 5 June 2023
- journal article
- research article
- Published by Wiley in United European Gastroenterology Journal
- Vol. 11 (7) , 633-641
Abstract
Background and AimsPolycystic liver disease (PLD) can lead to extensive hepatomegaly. Symptom relief is the primary goal of the treatment. The role of the recently developed disease-specific questionnaires for identification of the thresholds and the assessment of therapy needs further investigation. MethodsA five-year prospective multi-centric observational study in 21 hospitals in Belgium gathered a study population of 198 symptomatic PLD-patients of whom the disease-specific symptom questionnaire PLD-complaint-specific assessment (POLCA) scores were calculated. The thresholds of the POLCA score for the need for volume reduction therapy were analyzed. ResultsThe study group consisted of mostly (82.8%) women with baseline mean age of 54.4 years +/- 11.2, median liver volume expressed as height-adjusted total liver volume(htLV) of 1994 mL (interquartile range [IQR] 1275; 3150) and median growth of the liver of +74 mL/year (IQR +3; +230). Volume reduction therapy was needed in 71 patients (35.9%). A POLCA severity score (SPI) >= 14 predicted the need for therapy both in the derivation (n = 63) and the validation cohort (n = 126). The thresholds to start somatostatin analogues (n = 55) or to consider liver transplantation (n = 18) were SPI scores of >= 14 and >= 18 and the corresponding mean htLVs were 2902 mL (IQR 1908; 3964) and 3607 mL (IQR 2901; 4337), respectively. Somatostatin analogues treatment resulted in a decrease in the SPI score -6.0 versus + 4.5 in patients without somatostatin analogues (p < 0.01). Changes in the SPI score were significantly different between the liver transplantation group and no liver transplantation group, +4.3 +/- 7.1 versus -1.6 +/- 4.9, respectively, (p < 0.01). ConclusionA polycystic liver disease-specific questionnaire can be used as a guide on when to start a volume reduction therapy and to assess the effect of treatment.Keywords
Funding Information
- Ipsen Fund
This publication has 28 references indexed in Scilit:
- Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic valueLiver Transplantation, 2012
- Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry studyTransplant International, 2011
- Systematic review: the pathophysiology and management of polycystic liver diseaseAlimentary Pharmacology & Therapeutics, 2011
- Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 casesLiver International, 2010
- Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver DiseaseJournal of the American Society of Nephrology, 2010
- Reducing Polycystic Liver Volume in ADPKDClinical Journal of the American Society of Nephrology, 2010
- Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled TrialGastroenterology, 2009
- Model for end-stage liver disease (MELD) exception for polycystic liver diseaseLiver Transplantation, 2006
- Clinical profile of autosomal dominant polycystic liver diseaseHepatology, 2003
- Liver transplantation for polycystic liver diseaseLiver Transplantation, 2001